Friday, July 10, 2026

pharma · Malignant Pleural Mesothelioma · Bipolar I Depression

Sumitomo Pharma Co

Sumitomo Pharma Co clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

JP HQ
1897 Founded
193 Employees
NMPA registrant Type
Company details
Status
Public
HQ
JP
Founded
1897
Employees
193
Programs
4
Drugs
3
Patents
0
Intelligence · Clinical Programs

Sumitomo Pharma Co projects

4 ClinicalTrials.gov programs sponsored by Sumitomo Pharma Co.

Sumitomo Pharma Co has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Lurasidone

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar I Depression

    phase 3 small molecule completed

    1 trial
  2. Napabucasin

    Sumitomo Pharma (Suzhou) Co.,

    Carcinoma, Pancreatic Ductal

    phase 3 small molecule completed

    1 trial
  3. Placebo

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar Depression

    phase 3 small molecule completed

    1 trial
  4. BBI608

    Sumitomo Pharma (Suzhou) Co.,

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Sumitomo Pharma Co have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.